Precision BioSciences/DTIL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Precision BioSciences

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

Ticker

DTIL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Amoroso

Employees

109

Headquarters

Durham, United States

DTIL Metrics

BasicAdvanced
$89M
Market cap
-
P/E ratio
-$7.41
EPS
1.73
Beta
-
Dividend rate
$89M
1.72873
$25.20
$8.25
92K
4.824
60.367
-10.27%
-51.66%
-12.94%
1.553
2.398
2.426
88.25%
51.20%
26.13%

What the Analysts think about DTIL

Analyst Ratings

Majority rating from 6 analysts.
Buy

DTIL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
48.57% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
150.00%
Net income
$8.5M
-152.47%
Profit margin
48.57%
-120.99%

DTIL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 188.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.00
-$2.10
-$4.06
$1.70
-
Expected
-$7.32
-$4.88
-$2.05
-$1.91
-$1.51
Surprise
-59.02%
-56.92%
98.29%
-188.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Precision BioSciences stock?

Precision BioSciences (DTIL) has a market cap of $89M as of June 17, 2024.

What is the P/E ratio for Precision BioSciences stock?

The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 0 as of June 17, 2024.

Does Precision BioSciences stock pay dividends?

No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Precision BioSciences dividend payment date?

Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.

What is the beta indicator for Precision BioSciences?

Precision BioSciences (DTIL) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Precision BioSciences stock price target?

The target price for Precision BioSciences (DTIL) stock is $33, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Precision BioSciences stock

Buy or sell Precision BioSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing